The inositol trisphosphate pathway mediates platelet-activating-factor-induced pulmonary oedema

European Respiratory Journal

Volumn 25, Issue 5, 2005, Pages 849-857

  Goggel R ^a   Uhlig, S ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Calcium; Myosin light chain kinase; Phosphatidyl inositol specific phospholipase C; Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 5 IODONAPHTHALENE 1 SULPHONYLHOMOPIPERAZINE; ACETYLSALICYLIC ACID; CALCIUM; EDELFOSINE; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; INOSITOL TRISPHOSPHATE; MYOSIN LIGHT CHAIN KINASE INHIBITOR; PHOSPHOLIPASE C; RHO KINASE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; XESTOSPONGIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; EXTRACELLULAR CALCIUM; FEMALE; HYPOTHESIS; ISOLATED LUNG; LUNG EDEMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY ARTERY; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM; DISEASE MODELS, ANIMAL; ENDOTHELIUM; FEMALE; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MYOSIN-LIGHT-CHAIN KINASE; ORGAN SIZE; PLATELET ACTIVATING FACTOR; PROTEIN-SERINE-THREONINE KINASES; PULMONARY EDEMA; RATS; RATS, WISTAR; REFERENCE VALUES;

EID: 18744403445     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00069804     Document Type: Article

References (74)

1. Hosford D, Koltai M, Paubert-Braquet M, Braquet P. Analysis of platelet-activating factor in endotoxic shock and sepsis using a probability matrix: a critique of meta-analysis. In: Neugebauer EA, Holaday JW, eds. Handbook of Mediators in Septic Shock. Boca Raton, FL, CRC Press, 1994; pp. 439-456.
2. Christie PE, Henderson WR. Lipid inflammatory mediators: leukotrienes, prostaglandins, platelet-activating factor. Clin Allergy Immunol 2002; 16: 233-254.
3. Uhlig S, Wollin L, Wendel A. Contributions of thromboxane and leukotrienes to platelet-activating factor-induced impairment of lung function in the rat. J Appl Physiol 1994; 77: 262-269.
4. Martin C, Göggel R, Ressmeyer AR, Uhlig S. Pressor responses to platelet-activating factor and thromboxane are mediated by Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004; 287: L250-L257.
5. 2, EP3-receptors and potassium channels. Am J Respir Crit Care Med 2002; 166: 657-662.
6. Göggel R, Winoto-Morbach S, Vielhaber G, et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 2004; 10: 155-160.
7. Falk S, Göggel R, Heydasch U, et al. Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation. Am J Respir Crit Care Med 1999; 160: 1734-1742.
8. Misra UK, Gawdi G, Pizzo SV. Chloroquine, quinine and quinidine inhibit calcium release from macrophage intracellular stores by blocking inositol 1,4,5-trisphosphate binding to its receptor. J Cell Biochem 1997; 64: 225-232.
9. 2 activation and induction of interleukin 1β and tumor necrosis factor-α in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 1998; 30: 357-366.
10. 2 on leukotriene and histamine release from human and guinea-pig lung. Prostaglandins 1985; 30: 199-208.
11. Shute JK, Smith ME. Inhibition of phosphatidylinositol phosphodiesterase activity in skeletal muscle by metal ions and drugs which block neuromuscular transmission. Biochem Pharmacol 1985; 34: 2471-2475.
12. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001; 70: 281-312.
13. Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev 2000; 80: 1291-1335.
14. Bolton TB, Prestwich SA, Zholos AV, Gordienko DV. Excitation-contraction coupling in gastrointestinal and other smooth muscles. Annu Rev Physiol 1999; 61: 85-115.
15. 2+ signaling in the regulation of endothelial permeability. Vascul Pharmacol 2002; 39: 173-185.
16. Kester M, Thomas CP, Wang J, Dunn MJ. Platelet-activating factor stimulates multiple signaling pathways in cultured rat mesangial cells. J Cell Physiol 1992; 153: 244-255.
17. Stevens T, Garcia JG, Shasby DM, Bhattacharya J, Malik AB. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung Cell Mol Physiol 2000; 279: L419-L422.
18. Garcia JGN, Siflinger-Birnboim A, Bizios R, DelVecchio PJ, Fenton JW, Malik AB. Thrombin-induced increase in albumin permeability across the endothelium. J Cell Physiol 1986; 128: 96-104.
19. Carbajal JM, Gratrix ML, Yu CH, Schaeffer RC. ROCK mediates thrombin's endothelial barrier dysfunction. Am J Physiol Cell Physiol 2000; 279: C195-C204.
20. Dudek SM, Garcia JGN. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001; 91: 1487-1500.
21. Wainwright MS, Rossi J, Schavocky J, et al. Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment. Proc Natl Acad Sci U S A 2003; 100: 6233-6238.
22. Smith LJ, Rubin AE, Patterson R. Mechanism of platelet activating factor-induced bronchoconstriction in humans. Am Rev Respir Dis 1988; 137: 1015-1019.
23. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-445.
24. Sirois MG, de Lima WT, Brum Fernandes AJ, Johnson RJ, Plante GE, Sirois P. Effect of PAF on rat lung vascular permeability: role of platelets and polymorphonuclear leucocytes. Br J Pharmacol 1994; 111: 1111-1116.
25. Toga H, Hibler S, Ibe BO, Usha-Raj J. Vascular effects of platelet-activating factor in lambs: role of cyclo- and lipoxygenase. J Appl Physiol 1992; 73: 2559-2566.
26. Argiolas L, Fabi F, Basso PD. Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclooxygenase metabolites. Br J Pharmacol 1995; 114: 203-209.
27. Chlopicki S, Olszanecki R, Jawien J, Bartus JB, Gryglewski RJ. Residual pulmonary neutrophils are involved in vaso- and bronchoconstrictor responses to platelet activating factor in the isolated buffer-perfused rat lung. Pol J Pharmacol 2000; 52: 217-222.
28. Hamasaki Y, Mojarad M, Saga T, Tai HH, Said SI. Platelet-activating factor raises airway and vascular resistance and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis 1984; 129: 742-748.
29. Uhlig S, Heiny O. Measuring the weight of the isolated perfused rat lung during negative pressure ventilation. J Pharmacol Toxicol Methods 1995; 33: 147-152.
30. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanisms of action of some commonly used protein kinase inhibitors. Biochem J 2000; 531: 95-105.
31. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol Pharmacol 2000; 57: 976-983.
32. Powis G, Seewald MJ, Gratas C, Melder D, Riebow J, Modest EJ. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res 1992; 52: 2835-2840.
33. Saitoh M, Ishikawa T, Matsushima S, Naka M, Hidaka H. Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J Biol Chem 1987; 262: 7796-7801.
34. 2+/calmodulin-dependent protein kinase II by K252a and its derivative, KT5926. Biochem Biophys Res Commun 1991; 181: 423-429.
35. Kase H, Iwahashi K, Nakanishi S, et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 1987; 142: 436-440.
36. Yamada K, Iwahashi K, Kase H. K252a, a new inhibitor of protein kinase C, concomitantly inhibits 40K protein phosphorylation and serotonin secretion in phorbol ester-stimulated platelets. Biochem Biophys Res Commun 1987; 144: 35-40.
37. Uhlig S, Wollin L. An improved setup for the isolated perfused rat lung. J Pharmacol Toxicol Methods 1994; 31: 85-94.
38. Uhlig S. The isolated perfused lung. In: Uhlig S, Taylor AE, eds. Methods in Pulmonary Pharmacology. Basle, Birkhäuser, 1998; pp. 29-55.
39. Uhlig S, von Bethmann AN. Determination of vascular compliance, interstitial compliance and capillary filtration coefficient in isolated perfused rat lungs. J Pharmacol Toxicol Methods 1997; 32: 119-127.
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat 1995; 57: 289-300.
41. Curran-Everett D. Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1-R8.
42. 2+ waves preferentially originate at specific loci in caveolin-rich cell edges. Proc Natl Acad Sci U S A 1998; 95: 5009-5014.
43. 3. Pflugers Arch 1999; 437: 305-314.
44. Hocking D, Ferro TJ, Johnson A. Dextran sulfate and heparin inhibit platelet-activating factor-induced pulmonary edema. J Appl Physiol 1992; 72: 179-185.
45. Oshiro T, Kakuta Y, Shimura S, Nara M, Shirato K. Characterization of platelet-activating factor-induced cytosolic calcium mobilization in human eosinophils. Clin Exp Allergy 2000; 30: 699-705.
46. Parekh AB, Penner R. Store depletion and calcium influx. Physiol Rev 1997; 77: 901-930.
47. Clough G. Relationship between microvascular permeability and ultrastructure. Prog Biophys Mol Biol 1991; 55: 47-69.
48. Nicolaysen G. Intravascular concentrations of calcium and magnesium ions and edema formation in isolated lungs. Acta Physiol Scand 1971; 81: 325-339.
49. Garcia JG, Verin AD, Schaphorst KL. Regulation of thrombin-mediated endothelial cell contraction and permeability. Semin Thromb Hemost 1996; 22: 309-315.
50. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371: 199-204.
51. 2+ sensitivity of light chain phosphorylation within smooth muscle cells. J Biol Chem 1994; 269: 9912-9920.
52. Chang SW, Feddersen CO, Henson PM, Voelkel NF. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987; 79: 1498-1509.
53. Carter MB, Wilson MA, Wead WB, Garrison RN. Platelet-activating factor mediates pulmonary macromolecular leak following intestinal ischemia-reperfusion. J Surg Res 1996; 60: 403-408.
54. Nagase T, Ishii S, Kume K, et al. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin Invest 1999; 104: 1071-1076.
55. Tschugguel W, Zhegu Z, Gajdzik L, Maier M, Graf J. High precision measurement of electrical resistance across endothelial cell monolayers. Pflugers Arch 1995; 430: 145-147.
56. Uhlig S, Lindner K. Novel mechanisms of endothelial cell permeability in the lung. Lessons from studies with intact lungs and animals. In: Tooke J, Shore A, Whatmore J, eds. The Microcirculation and Vascular Biology. Bologna, Monduzi Editore, 2002; pp. 221-234.
57. Dodam JR, Olson NC, Friedman M. Differential effects of tumor necrosis factor-α and platelet-activating factor on bovine pulmonary artery endothelial cells in vitro. Exp Lung Res 1994; 20: 131-141.
58. Bussolino F, Camussi G, Aglietta M, et al. Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol 1987; 139: 2439-2446.
59. Boschetto P, Rogers DF, Fabbri LM, Barnes PJ. Corticosteroid inhibition of airway microvascular leakage. Am Rev Respir Dis 1991; 143: 605-609.
60. 3 decreases scalding and platelet-activating factor-induced high vascular permeability edema. Pharmacol Toxicol 1995; 76: 365-367.
61. Ortiz JL, Vallés JM, Martí-Cabrera M, Cortijo J, Morcillo EJ. Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 200-206.
62. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993; 292: 617-629.
63. Mollinedo F, Gajate C, Martin-Santamaria S, Gago F. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem 2004; 11: 3163-3184.
64. Gafni J, Munsch JA, Lam TH, et al. Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron 1997; 19: 723-733.
65. Ozaki H, Hori M, Kim YS, et al. Inhibitory mechanism of xestospongin-C on contraction and ion channels in the intestinal smooth muscle. Br J Pharmacol 2002; 137: 1207-1212.
66. Mihai R, Lai T, Schofield G, Farndon JR. C2-ceramide increases cytoplasmic calcium concentrations in human parathyroid cells. Biochem Biophys Res Commun 2000; 268: 636-641.
67. 2+] in human airway epithelial cells. J Biol Chem 1994; 269: 4254-4259.
68. Katnik C, Nelson DJ. Platelet activating factor-induced increase in cytosolic calcium and transmembrane current in human macrophages. J Membr Biol 1993; 134: 213-224.
69. 2+ channel in human and canine aortic endothelial cells. Br J Pharmacol 1993; 110: 519-520.
70. 2+ entry. Am J Physiol 1999; 276: L41-L50.
71. Kamm KE, Stull JT. Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem 2001; 276: 4527-4530.
72. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22: 32-39.
73. 4- and histamine-induced airflow obstruction and airway microvascular leakage in guinea pigs in vivo. Pharmacology 2002; 64: 189-195.
74. Borbiev T, Verin AD, Shi S, Liu F, Garcia JG. Regulation of endothelial cell barrier function by calcium/calmodulindependent protein kinase II. Am J Physiol Lung Cell Mol Physiol 2001; 280: L983-L990.